CureVac (NASDAQ:CVAC) Receives “Hold” Rating from Jefferies Financial Group

Jefferies Financial Group reaffirmed their hold rating on shares of CureVac (NASDAQ:CVAC) in a research report released on Friday, MarketBeat Ratings reports. The firm currently has a $5.00 price objective on the stock, down from their prior price objective of $7.00.

Several other analysts also recently weighed in on CVAC. JMP Securities restated a “market outperform” rating and set a $10.00 price objective on shares of CureVac in a research report on Wednesday, May 28th. UBS Group lowered their target price on CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, April 30th.

CureVac Price Performance

Shares of CVAC stock opened at $5.57 on Friday. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. CureVac has a twelve month low of $2.37 and a twelve month high of $5.72. The company has a market cap of $1.25 billion, a P/E ratio of 10.13 and a beta of 2.49. The business has a fifty day simple moving average of $3.76 and a 200 day simple moving average of $3.48.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. On average, sell-side analysts forecast that CureVac will post 0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On CureVac

Institutional investors and hedge funds have recently bought and sold shares of the company. D. E. Shaw & Co. Inc. acquired a new position in CureVac in the 4th quarter worth about $66,000. Geode Capital Management LLC increased its stake in shares of CureVac by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company’s stock valued at $824,000 after buying an additional 22,491 shares during the period. Northern Trust Corp increased its stake in shares of CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company’s stock valued at $205,000 after buying an additional 29,759 shares during the period. Two Sigma Investments LP acquired a new stake in shares of CureVac in the fourth quarter valued at about $391,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of CureVac in the fourth quarter valued at about $48,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.